Therapies for rheumatoid arthritis: Hope springs eternal

Drug Discovery Today

Volumn 10, Issue 23-24, 2005, Pages 1598-1606

  Smith, Robert J ^a  

^a RJS Biomedical Communications   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [7 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRO 8 (4 PYRIDYL)PYRAZOLO[5,1 C][1,2,4]TRIAZIN 2 YL] 2 PHENYLETHANEDIONE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; 6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; ACETYLSALICYLIC ACID; ADALIMUMAB; AMG 548; ANALGESIC AGENT; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; ARTHROTEC; AZATHIOPRINE; BMS 345541; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DORAMAPIMOD; ETANERCEPT; HYDROXYCHLOROQUINE; IBUPROFEN; IMD 0560; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PARACETAMOL; PREDNISONE; PROTON PUMP INHIBITOR; R 130823; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RETROVIRUS VECTOR; RITUXIMAB; ROFECOXIB; SALAZOSULFAPYRIDINE; SB 242235; SC 514; SCIO 469; SPC 839; TPCA 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB; VX 702;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CHEMOTHERAPY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL IRRITATION; GASTROINTESTINAL SYMPTOM; GENETIC TRANSCRIPTION; HEART INFARCTION; HUMAN; INFLAMMATION; NONVIRAL GENE THERAPY; PAIN; PATHOGENESIS; REVIEW; RHEUMATOID ARTHRITIS; STROKE; TREATMENT OUTCOME; VIRAL GENE THERAPY;

EID: 29144443866     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03636-6     Document Type: Short Survey

References (78)

1. G.S. Firestein Etiology and pathogenesis of rheumatoid arthritis Ruddy S. Kelley's Textbook of Rheumatology 2001 W.B.Saunders company 921 966
2. A.F. Kavanaugh, P.E. Lipsky Rheumatoid Arthritis Gallin J.I. Snyderman R. Inflammation- Basic Principles and Clinical Correlates 1999 Lippincott Williams and Wilkins 1017 1037
3. A. Rostom Cochrane Database Syst. Rev. 2000 CDOO2296
4. T.S. Bocanegra Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec osteoarthritis study group J. Rheumatol. 25 1998 1602 1611
5. J.L. Goldstein Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis Am. J. Gastroenterol. 96 2001 1019 1027
6. C.M. Weyand, J.J. Goronzy Ectopic germinal center formation in rheumatoid synovitis Ann. N. Y. Acad. Sci. 987 2003 140 149
7. B.N. Cronstein Second-line antirheumatic drugs Gallin J.I. Snyderman R. Inflammation- Basic Principles and Clinical Correlates 1999 Lippincott Williams and Wilkins 1227 1237
8. C.K. Kwoh Guidelines for the management of rheumatoid arthritis: 2002 update - American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines Arth Rheum. 46 2002 328 346
9. T. Pincus Early radiographic joint space narrowing and erosion and later malalignment in rheumatoid arthritis; a longitudinal study J. Rheumatol. 25 1998 636 640
10. C.M. Stein, T. Pincus Glucocorticoids Ruddy S. Kelley's Textbook of Rheumatology 2001 W.B. Saunders Company 823 840
11. Bijlsma J.W.J. Glucocorticoids in rheumatoid arthritis: effects on erosions and bone Ann. N. Y. Acad. Sci. 966 2002 82 90
12. H. Schacke SEGRAs: a novel class of anti-inflammatory compounds Ernst Schering Res. Found. Workshop 40 2002 357 371
13. F. Buttgereit Current insights into the development of new glucocorticoid receptor ligands Z. Rheumatol. 64 2005 170 176
14. I.H. Song New glucocorticoids on the horizon: repress, don't activate! J. Rheumatol. 32 2005 1199 1207
15. H. Schacke Dissociated glucocorticoid receptor ligands: compounds with an improved therapeutic index Curr. Opin. Investig. Drugs 6 2005 503 507
16. Choy E.H.S., Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis N. Engl. J. Med. 344 2001 907 916
17. M. Feldman Role of cytokines in rheumatoid arthritis Annu. Rev. Immunol. 14 1996 397 440
18. L.H. Calabrese Molecular differences in anticytokine therapies Clin. Exp. Rheumatol. 21 2003 241 248
19. R.J. Smith Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness Arthritis Rheum. 34 1991 78 83
20. W.P. Arend Interleukin-1 receptor antagonist: role in biology Annu. Rev. Immunol. 16 1998 27 55
21. M.C. Genovese Etanercept versus methotrexate in patients with early rheumatoid arthritis: two year radiographic and clinical outcomes Arthritis Rheum. 46 2002 1443 1450
22. B. Bresnihan Preventing joint damage as the best measure of biologic drug therapy J. Rheumatol. Suppl. 65 2002 39 43
23. E.C. Keystone Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial Arthritis Rheum. 50 2004 1400 1411
24. H.M. Lorenz, J.R. Kalden Perspectives for TNF-alpha-targeting therapies Arthritis Res. 4 suppl 3 2002 S17 S24
25. N. Nishimoto Treatment of rheumatoid arthritis with humanized anti-interleukin 6 receptor antibody Arthritis Rheum. 50 2004 1761 1769
26. S. Yokota Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathetic arthritis Arthritis Rheum. 52 2005 818 825
27. M.S. Czuczman Rituximab I combination with CHOP or fludarabine in low-grade lymphoma Semin. Oncol. 29 2002 36 40
28. J. Edwards Efficacy of B-cell target therapy with rituximab in patients with rheumatoid arthritis N. Engl. J. Med. 350 2004 2572 2581
29. M. Calguneri Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis Clin. Exp. Rheumatol. 17 1999 699 704
30. T. Mottonen Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomized trial Lancet 353 1999 1568 1573
31. O'Dell J.R. Treatment of rheumatoid arthritis with methotrexate and hydrochloroquine, and methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial Arthritis Rheum. 46 2002 1164 1170
32. M.C. Genovese Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate Arthritis Rheum. 50 2004 1412 1419
33. E.M. Ruderman, R.M. Pope The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis Arthritis Res. Ther. 7 suppl 2 2005 s21 s25
34. J.M. Kremer Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb double-blind, randomized, placebo-controlled trial Arthritis Rheum. 52 2005 2263 2271
35. C.J. Dunn, K.L. Goa Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease Drugs 61 2001 685 712
36. S. Jarrett First evidence of structural benefit from a bisphosphonate, zoledronic acid, in rheumatoid arthritis EULAR 2004 2004 9 12 June 2004, Berlin, Germany (Abstract 0P0002)
37. M. Chuah Challenges in advancing the field of gene therapy - American Society of Gene Therapy Stockholders Meeting. A critical review of the science, medicine and regulation IDrugs 8 2005 483 486
38. C.H. Evans Gene therapy for rheumatic diseases Arthritis Rheum. 42 1999 1 16
39. R.Y. Pan Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist Arthritis Rheum. 43 2000 289 297
40. U. Dettweiler, P. Simon Points to consider for ethics committees in human gene therapy trials Bioethics 15 2001 491 500
41. C.H. Evans Gene transfer to human joints: progress toward a gene therapy for arthritis Proc. Natl. Acad. Sci. U. S. A. 102 2005 8698 8703
42. R.J. Verburg High dose chemotherapy and autologous hematopoietic stem cell transplantation for rheumatoid arthritis Hum. Immunol. 63 2002 627 637
43. R.J. Verburg High dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: results of an open study to assess feasibility, safety, and efficacy Arthritis Rheum. 44 2001 754 760
44. J.A. Snowden Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report form the EMBT and ABMRT J. Rheumatol. 31 2004 482 488
45. R.J. Verburg Reduction of joint damage in severe rheumatoid arthritis by high-dose chemotherapy and autologous stem cell transplantation Arthritis Rheum. 52 2005 421 424
46. S. Ghosh, M. Karin Missing pieces in the NF-kB puzzle Cell 109 2002 S81 S96
47. M.I. Vega Rituximab-induced inhibition of YY1 and BCL-xL expression in ramos non-hodgkin's lymphoma cell line via inhibition of NF-kB activity: role of YY1 and BCL-xL in fas resistance and chemoresistance, respectively J. Immunol. 175 2005 2174 2183
48. S.K. Manna Leflunomide suppresses TNF-induced cellular responses: effects on NF-kB, activator protein-1, c-Jun N-terminal kinase, and apoptosis J. Immunol. 165 2000 5962 5969
49. S. Majumdar, J. Aggarawal Methotrexate suppresses NF-kB activation through inhibition of IkBa phosphorylation and degradation J. Immunol. 167 2001 2911 2920
50. S. Shishodia Cycloxygenase (COX)-2 inhibitor Celecoxib abrogates TNF-induced NF-kB activation through inhibition of IkBa kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis J. Immunol. 173 2004 2011 2022
51. X.W. Meng Induction of apoptosis in peripheral blood lymphocytes following treatment in vitro with hydroxychloroquine Arthritis Rheum. 40 1997 927 935
52. E. Kopp, S. Ghosh Inhibition of NF-kappa B by sodium salicylate and aspirin Science 265 1994 956 959
53. J.C. Reed, M. Pellecchia Apoptosis-based therapies for hematologic malignancies Blood 106 2005 408 418
54. Mercurio F., Manning A.M. Multiple signals converging on NF-kB Curr. Opin. Cell Biol. 11 1999 226 232
55. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-kB activity Annu. Rev. Immunol. 18 2000 621 623
56. M. Karin How NF-kB is activated. The role of the IkB kinase (IKK) Oncogene 18 1999 6867 6874
57. N. Kishore A selective IKK-2 inhibitor blocks NF-kB dependent gene expression in Interleukin-1b-stimulated synovial fibroblasts J. Biol. Chem. 278 2003 32861 32871
58. K.W. McIntyre A selective inhibitor of IkB kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice Arthritis Rheum. 48 2003 2652 2659
59. Y. Okazaki Effect of Nuclear Factor-kB inhibition on rheumatoid fibroblast-like synoviocytes and collagen-induced arthritis J. Rheumatol. 32 2005 1440 1447
60. P.L. Podolin Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkB kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation J. Pharmacol. Exp. Ther. 312 2005 373 381
61. T. Hideshima NF-kappa B as a therapeutic target for multiple myeloma J. Biol. Chem. 277 2002 16639 16647
62. M.J. Yin The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta Nature 396 1998 77 80
63. D. Hammaker Signal transduction networks in rheumatoid arthritis Ann. Rheum. Dis 62 Suppl II 2003 ii86 ii89
64. G.S. Firestein, A.M. Manning Signal transduction and transcription factors in rheumatic disease Arth. Rheum. 42 1999 609 621
65. G. Pearson Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions Endocr. Rev. 22 2001 153 183
66. C. Fearns Coordinate activation of endogenous p38a, b, g, and d by inflammatory stimuli J. Leuk. Biol. 67 2000 705 711
67. A.M. Badger Differential effects of SB-242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/chondrocyte cultures Osteoarthritis Cartilage 8 2000 434 443
68. J. Westra Effects of RWJ-67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts Ann. Rheum. Dis. 63 2004 1453 1459
69. Y.H. Wei Effects and mechanisms of FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor, on adjunvant arthritis in rats Int. Immunopharmacol. 4 2004 1625 1632
70. C. Dominguez p38 kinase inhibitors: many are made but few are chosen Curr. Opin. Drug Discov. Devel. 8 2005 421 430
71. Y. Kuma BIRB 796 inhibits all p38 isoforms in vitro and in vivo J. Biol. Chem. 280 2005 19472 19479
72. Y. Wada Novel p38 MAP kinase inhibitor R-130823 suppresses IL-6, IL-8 and MMP-13 production on spheroid culture of human synovial sarcoma cell line SW 982 Immunol. Lett. 101 2005 50 59
73. Y. Wada R-130823, a novel inhibitor of p38 MAPK, ameliorates hyperalgesia and swelling in arthritis models Eur. J. Pharmacol. 506 2005 285 295
74. C. Dominguez p38 kinase inhibitors: many are made but few are chosen Curr. Opin. Drug Discov. Devel. 8 2005 421 430
75. S.N. Nikas, A.A. Drosos SCIO-469 Scios Inc. Curr. Opin. Investig Drugs 5 2004 1205 1212
76. Z. Han c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis J. Clin. Invest. 108 2001 73 81
77. J. Saklatvala Control of the expression of inflammatory response genes Biochem. Soc. Symp. 70 2003 95 106
78. S. Saccani p38-dependent marking of inflammatory genes for increased NF-kappa B recruitment Nat. Immunol. 3 2002 69 75